基于“大气”理论论治高危特发性膜性肾病

张林; 薛小琴; 胡樱丽; 王喜红; 梁峰; 唐阁

doi:10.3969/j.issn.1673-7202.2021.07.018

意见反馈

您当前的位置：

首页 >

文章列表页 >

基于“大气”理论论治高危特发性膜性肾病

中国中医药临床案例成果库 | 临证体会

上一篇: 李晶治疗消化道肿瘤经验

下一篇: 从“六对论治”谈国医大师吕仁和教授茵陈应用经验

基于“大气”理论论治高危特发性膜性肾病
Treatment of High Risk Idiopathic Membranous Nephropathy Based on "Da Qi"
1.天津中医药大学第一附属医院，天津，300193
DOI：10.3969/j.issn.1673-7202.2021.07.018

扫描看全文

张林, 薛小琴, 胡樱丽, 等. 基于“大气”理论论治高危特发性膜性肾病[DB/OL].（2023-09-15）[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails#10.3969/j.issn.1673-7202.2021.07.018

ZHANG Lin, XUE Xiaoqin, HU Yingli, et al. Treatment of High Risk Idiopathic Membranous Nephropathy Based on "Da Qi"[DB/OL].（2023-09-15）[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails#10.3969/j.issn.1673-7202.2021.07.018
张林, 薛小琴, 胡樱丽, 等. 基于“大气”理论论治高危特发性膜性肾病[DB/OL].（2023-09-15）[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails#10.3969/j.issn.1673-7202.2021.07.018 DOI：

ZHANG Lin, XUE Xiaoqin, HU Yingli, et al. Treatment of High Risk Idiopathic Membranous Nephropathy Based on "Da Qi"[DB/OL].（2023-09-15）[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails#10.3969/j.issn.1673-7202.2021.07.018 DOI：

摘要

膜性肾病（Membranous Nephropathy，MN）是一种慢性肾脏疾病，发病高峰期在30～50岁，60%～80%膜性肾病表现为肾病综合征。特发性膜性肾病（Idiopathic Membranous Nephropathy，IMN），约占膜性肾病的2/3，根据尿蛋白的量可以分成低危、中危、高危3个等级。中医学认为，“大气”亏虚是高危IMN的发病原因，进而导致“大气”“滞而不运、脱而不升、散而不聚”的病理状态，临床根究“大气”的不同病理状态，可以从“补气清源、活血澄源、固肾复源”3方面来治疗高危IMN，对临床有一定指导意义。

Abstract

Membranous Nephropathy (MN) is a kind of chronic nephritic disease. The peak period of onset is from 30 to 50 years old, and 60% to 80% of membranous nephropathy is characterized by nephrotic syndrome (NS) . Idiopathic Membranous Nephropa-thy (IMN) accounts for about 2/3 of membranous nephropathy. According to the amount of urine protein, it can be divided into three grades: the low, medium and high-risk. TCM holds that "Da Qi" deficiency is the etiology of high-risk IMN, leading "Da Qi" to the pathology of "delay shipment, and do not rise, butnot to get together" . Clinical research on the different pathological states of "Da Qi" shows that high-risk IMN from three aspects of "tonifying qi and clearing the source, promoting blood circulation and clar-ifying the source, and strengthening the kidney and restoring the source", which has certain guiding significance for clinical prac-tice.

关键词

高危特发性膜性肾病大气蛋白尿感染血栓栓塞

Keywords

High riskIdiopathic membranous nephropathyDa QiProteinuriaInfectionThromboembolism

references

杨柳, 刘东伟, 刘章锁. 膜性肾病流行病学研究进展[J]. 中华肾脏病杂志, 2016, 32(3): 229-232.

刘英杰, 张启东, 郭维康, 等. 北京地区单中心2008~2018年特发性膜性肾病流行病学变迁[J]. 临床和实验医学杂志, 2019, 18(2): 181-183.

Hofstra JM, Wetzels JF. Management of patients with membranous ne-phropathy[J]. Nephrol Dial Transplant, 2012, 27(1): 6-9.

于澈, 王荣. 特发性膜性肾病诊疗指南解读[J]. 临床内科杂志, 2015, 32(8): 575-576.

黄智敏, 陈科杰. 环孢素A和环磷酰胺治疗特发性膜性肾病的疗效、复发率及副作用研究[J]. 北方药学, 2016, 13(9): 66.

Stangou M, Marinaki S, Papachristou E, et al. Immunosuppressive reg-imens based on Cyclophospamide or Calcineurin inhibitors: Compari-son of their effect in the long term outcome of Primary Membranous Nephropathy[J]. PLoS One, 2019, 14(8): e0217116

孙洁雨, 郭宏丽, 许静. 钙调磷酸酶抑制剂在儿童难治性肾病综合征中的应用进展[J]. 中国新药杂志, 2018, 27(13): 1515-1520.

苏艳. 特发性膜性肾病治疗反应的影响因素[J]. 深圳中西医结合杂志, 2019, 29(8): 171-173.

Zhang BO, Cheng M, Yang M, et al. Analysis of the prognostic risk factors of idiopathic membranous nephropathy using a new surrogate end-point[J]. Biomed Rep, 2016, 4(2): 147-152.

李怡然, 解汝娟, 隋满姝, 等. 膜性肾病的临床病理特点及肾小球滤过率下降的危险因素[J]. 临床与病理杂志, 2018, 38(11): 2409-2415.

Yokoyama H, Taguchi T, Sugiyama H, et al. Membranous nephropa-thy in Japan: Analysis of the Japan Renal Biopsy Registry(J-RBR)[J]. Clin Exp Nephrol, 2012, 16(4): 557-563.

张谈, 裘雯慧, 王斌, 等. 张迪蛟“转大气”临床验案四则[J]. 中华中医药杂志, 2011, 26(4): 736-738.

丁英钧, 蔡冀民, 潘莉, 等. 慢性肾脏病“肾络淤阻”共有病机学说及临床意义[J]. 时珍国医国药, 2011, 22(3): 690-691.

支勇, 赵巍, 曹式丽. 曹式丽运用辛通畅络法治疗膜性肾病经验[J]. 中医杂志, 2019, 60(17): 1459-1462.

Ahmed MS, Hou SH, Battaglia MC, et al. Treatment of idiopathic membranous nephropathy with herb Astragalusmembranceus[J]. Am J Kidney Dis, 2007, 50(6): 1028-1032.

Song X, Mo W, Liu X. The NMR solution structure of recombinant RGD-hirudin[J]. Biochem Biophys Res Commun, 2007, 360(1): 103.

金劲松. 水陆二仙丹治疗肾病综合征大鼠蛋白尿的作用机理研究[D]. 武汉: 湖北中医学院, 2007.

余凌, 李惊子, 王海燕, 等. 黄芪当归在肾脏疾病中的应用及其机制研究进展[J]. 中国中西医结合杂志, 2001, 21(5): 396-398.

Song X, Mo W, Liu X. The NMR solution structure of recombinant RGD-hirudin[J]. Biochem Biophys Res Commun, 2007, 360(1): 103.

倪丽, 石咏军, 刘珍珍, 等. 影响特发性膜性肾病患者预后的危险因素分析[J]. 中国中西医结合肾病杂志, 2018, 19(4): 321-323.

陈敬民, 李友娣. 金樱子醇提物对被动型Heymann肾炎大鼠的药理作用研究[J]. 中药材, 2005, 28(5): 408-410.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

曹式丽从湿热论治蛋白尿学术经验

李平经方合用治疗乙型肝炎病毒性相关肾炎的经验

基于三焦气化理论辨治特发性膜性肾病

曹式丽从湿热论治蛋白尿学术经验

李平经方合用治疗乙型肝炎病毒性相关肾炎的经验